---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009309"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:35:46.058050+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988

## Summary
- First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
- CDI-988 is a direct-acting oral antiviral targeting 3CL protease; no approved norovirus treatments or vaccines exist.
- Study to enroll up to 40 healthy subjects; primary endpoint is reduction of clinical symptoms vs placebo.
- CDI-988 previously showed favorable safety in Phase 1; global norovirus economic burden estimated at $60B annually.
- FDA issued Study May Proceed Letter in Sep 2025; Emory IRB approval obtained Dec 2025.

## SEC filing metadata
- accession: 0001493152-26-009309
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/0001493152-26-009309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009309
- JSON: https://secwatch.observer/filing/0001493152-26-009309.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.